{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:06:57Z","timestamp":1789387617109,"version":"build-2803163510"},"reference-count":310,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FRN-142316, PJT-178120, FRN-175428, PJT-186267"],"award-info":[{"award-number":["FRN-142316, PJT-178120, FRN-175428, PJT-186267"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2019-04786"],"award-info":[{"award-number":["RGPIN-2019-04786"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Queen Elizabeth II Graduate Scholarship in Science and Technology from the Ontario Provincial Government"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Recently instituted world-wide newborn screening programs for spinal muscular atrophy (SMA) permit identification of at-risk individuals prior to clinical presentation of the disease. Early intervention with one or more of the available disease-modifying therapies has dramatically changed the clinical course for individuals affected by SMA. These therapies that yield such impressive results in pediatric SMA populations frequently provide more muted responses in adolescent and adult individuals with SMA. Many treated individuals experience plateau effects and pursue combination treatments to hopefully boost functional outcomes. In addition, individuals with SMA are also now living longer and experience altered disease phenotypes and challenges, such as severe and progressive scoliosis, bulbar issues and neurocognitive issues. Thus, although recent years are marked by significant advances in our understanding of disease pathogenesis and in the development and implementation of therapies to treat SMA, there are still ongoing challenges and unmet needs that will require new and innovate solutions to more fully address the needs of individuals with SMA. In this review, we provide an overview of SMA disease, including a discussion of the many diverse primary defects that have been documented in many different tissues of individuals with SMA and models of the disease, and provide an overview of the therapeutics currently available and in development to treat SMA.<\/jats:p>","DOI":"10.1177\/17562864261480901","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:43:14Z","timestamp":1789159394000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Spinal muscular atrophy: Biology, pathogenesis, and therapeutic advances"],"prefix":"10.1177","volume":"19","author":[{"given":"Charlotte A.","family":"Ren\u00e9","sequence":"first","affiliation":[{"name":"Ottawa Hospital Research Institute"},{"name":"University of Ottawa"},{"name":"University of Ottawa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4959-2233","authenticated-orcid":false,"given":"Robin J.","family":"Parks","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute"},{"name":"University of Ottawa"},{"name":"University of Ottawa"},{"name":"The Ottawa Hospital and University of Ottawa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2015.07.004"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000741"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2011.134"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2024.1911"},{"key":"e_1_3_5_6_2","unstructured":"AveXis. AveXis receives FDA approval for Zolgensma\u00ae the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA). https:\/\/www.novartis.com\/news\/media-releases\/avexis-receives-fda-approval-zolgensma-first-and-only-gene-therapy-pediatric-patients-spinal-muscular-atrophy-sma (2019 accessed October 11 2022 2022)."},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1515\/tnsci-2017-0001"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01410-z"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0671-8"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90460-3"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1996.0147"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/8.7.1177"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.11.6307"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2007.070399"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01262-08"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167087"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaa075"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157896"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/338627"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.33474"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.01.003"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2016.00007"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/9.1.47"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/6.8.1205"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb00725.x"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.98.1.358"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4827(91)90496-H"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature07677"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkl374"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi168"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0050073"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1089\/104303403321070874"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-90083-3"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2014.04.026"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80367-0"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80368-2"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M702317200"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M607505200"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1074962"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1101-945"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(01)00316-5"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddp009"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e02-04-0216"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1242\/bio.018804"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a003558"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200304128"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3631-10.2011"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/dds474"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddu350"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature16469"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2009.05.009"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq021"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1600015113"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2017.01.005"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-020-00845-w"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.021766"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddw262"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05573-x"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI124120"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddaa146"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.18.9920"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.06.043"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20120241"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M108769200"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddt254"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M414328200"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2185"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.908401"},{"key":"e_1_3_5_69_2","first-page":"3664","article-title":"The Tudor protein survival motor neuron (SMN) is a chromatin-binding protein that interacts with methylated lysine 79 of histone H3","volume":"126","author":"Sabra M","year":"2013","unstructured":"Sabra M, Texier P, El Maalouf J, et al. The Tudor protein survival motor neuron (SMN) is a chromatin-binding protein that interacts with methylated lysine 79 of histone H3. J Cell Sci 2013; 126: 3664\u20133677, 20130607. https:\/\/doi.org\/10.1242\/jcs.126003","journal-title":"J Cell Sci"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2012.08.025"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molbrainres.2003.08.011"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/8.13.2351"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.53.37908"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0598-63"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2012.08.024"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1884910"},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2004.09.024"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.147.6.1181"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1038\/35070059"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M309218200"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.embor.embor863"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112405"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.21308"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.20.11167"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi078"},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.372318"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01776636"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01668496"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-8966(99)00016-4"},{"key":"e_1_3_5_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/0960-8966(94)00075-K"},{"key":"e_1_3_5_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1090-3798(99)80012-9"},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1090-3798(99)80015-4"},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25101"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/0960-8966(94)90090-6"},{"key":"e_1_3_5_95_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1995.00540290108025"},{"key":"e_1_3_5_96_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314292"},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-0929-0"},{"key":"e_1_3_5_98_2","doi-asserted-by":"publisher","DOI":"10.1177\/0883073807305788"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.05.011"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.004"},{"key":"e_1_3_5_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.005"},{"key":"e_1_3_5_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.06.459"},{"key":"e_1_3_5_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(22)00342-X"},{"key":"e_1_3_5_104_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2024.0492"},{"key":"e_1_3_5_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-64142-7.00057-6"},{"key":"e_1_3_5_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2021.06.008"},{"key":"e_1_3_5_107_2","doi-asserted-by":"publisher","DOI":"10.1159\/000007926"},{"key":"e_1_3_5_108_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27031270"},{"key":"e_1_3_5_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70271-6"},{"key":"e_1_3_5_110_2","first-page":"290","article-title":"Clinical practice guidelines for the diagnosis and management of Charcot-Marie-Tooth disease","volume":"40","author":"Sivera Mascaro R","year":"2025","unstructured":"Sivera Mascaro R, Garcia Sobrino T, Horga Hernandez A, et al. Clinical practice guidelines for the diagnosis and management of Charcot-Marie-Tooth disease. Neurologia (Engl Ed) 2025; 40: 290\u2013305, Practice Guideline 2024\/03\/03. https:\/\/doi.org\/10.1016\/j.nrleng.2024.02.008","journal-title":"Neurologia (Engl Ed)"},{"key":"e_1_3_5_111_2","doi-asserted-by":"publisher","DOI":"10.31083\/RN48384"},{"key":"e_1_3_5_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60921-6"},{"key":"e_1_3_5_113_2","doi-asserted-by":"publisher","DOI":"10.2174\/15665240113139990044"},{"key":"e_1_3_5_114_2","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2014.00293"},{"key":"e_1_3_5_115_2","doi-asserted-by":"publisher","DOI":"10.1177\/0883073807305787"},{"key":"e_1_3_5_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0929-693X(20)30274-8"},{"key":"e_1_3_5_117_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/93.1.15"},{"key":"e_1_3_5_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(71)90249-8"},{"key":"e_1_3_5_119_2","doi-asserted-by":"publisher","DOI":"10.4322\/acr.2020.157"},{"key":"e_1_3_5_120_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10050"},{"key":"e_1_3_5_121_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15005"},{"key":"e_1_3_5_122_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880090106"},{"key":"e_1_3_5_123_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2021-000164"},{"key":"e_1_3_5_124_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182749eca"},{"key":"e_1_3_5_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.07.007"},{"key":"e_1_3_5_126_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2012.11.002"},{"key":"e_1_3_5_127_2","doi-asserted-by":"publisher","DOI":"10.2174\/1566524016666161128113338"},{"key":"e_1_3_5_128_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2020.01.003"},{"key":"e_1_3_5_129_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-221567"},{"key":"e_1_3_5_130_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq340"},{"key":"e_1_3_5_131_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25549"},{"key":"e_1_3_5_132_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000200193"},{"key":"e_1_3_5_133_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-023-05397-z"},{"key":"e_1_3_5_134_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq300"},{"key":"e_1_3_5_135_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq329"},{"key":"e_1_3_5_136_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq330"},{"key":"e_1_3_5_137_2","doi-asserted-by":"publisher","DOI":"10.1111\/joa.12793"},{"key":"e_1_3_5_138_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2008.057950"},{"key":"e_1_3_5_139_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.50855"},{"key":"e_1_3_5_140_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14182078"},{"key":"e_1_3_5_141_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI173702"},{"key":"e_1_3_5_142_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105444"},{"key":"e_1_3_5_143_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01367-y"},{"key":"e_1_3_5_144_2","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2012.222"},{"key":"e_1_3_5_145_2","doi-asserted-by":"publisher","DOI":"10.1111\/joa.12546"},{"key":"e_1_3_5_146_2","first-page":"801","article-title":"Immune dysregulation may contribute to disease pathogenesis in spinal muscular atrophy mice","volume":"26","author":"Deguise MO","year":"2017","unstructured":"Deguise MO, De Repentigny Y, McFall E, et al. Immune dysregulation may contribute to disease pathogenesis in spinal muscular atrophy mice. Hum Mol Genet 2017; 26: 801\u2013819. https:\/\/doi.org\/10.1093\/hmg\/ddw434","journal-title":"Hum Mol Genet"},{"key":"e_1_3_5_147_2","first-page":"932","article-title":"SMN deficiency negatively impacts red pulp macrophages and spleen development in mouse models of spinal muscular atrophy","volume":"26","author":"Khairallah MT","year":"2017","unstructured":"Khairallah MT, Astroski J, Custer SK, et al. SMN deficiency negatively impacts red pulp macrophages and spleen development in mouse models of spinal muscular atrophy. Hum Mol Genet 2017; 26: 932\u2013941. https:\/\/doi.org\/10.1093\/hmg\/ddx008","journal-title":"Hum Mol Genet"},{"key":"e_1_3_5_148_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000353"},{"key":"e_1_3_5_149_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2023.10.006"},{"key":"e_1_3_5_150_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddaa126"},{"key":"e_1_3_5_151_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23582"},{"key":"e_1_3_5_152_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddu052"},{"key":"e_1_3_5_153_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28275"},{"key":"e_1_3_5_154_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.09.023"},{"key":"e_1_3_5_155_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2021.02.002"},{"key":"e_1_3_5_156_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv292"},{"key":"e_1_3_5_157_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155032"},{"key":"e_1_3_5_158_2","first-page":"1789","article-title":"Smooth muscle atrophy and colon pathology in SMN deficient mice","volume":"11","author":"Yang Y","year":"2019","unstructured":"Yang Y, Vassilakos G, Hammers DW, et al. Smooth muscle atrophy and colon pathology in SMN deficient mice. Am J Transl Res 2019; 11: 1789\u20131799, 20190315.","journal-title":"Am J Transl Res"},{"key":"e_1_3_5_159_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2008.02.008"},{"key":"e_1_3_5_160_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2005.08.019"},{"key":"e_1_3_5_161_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12740"},{"key":"e_1_3_5_162_2","doi-asserted-by":"publisher","DOI":"10.1186\/2044-5040-3-24"},{"key":"e_1_3_5_163_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI131989"},{"key":"e_1_3_5_164_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2009.01.071"},{"key":"e_1_3_5_165_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21654"},{"key":"e_1_3_5_166_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153430"},{"key":"e_1_3_5_167_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24549"},{"key":"e_1_3_5_168_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1941310"},{"key":"e_1_3_5_169_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1610"},{"key":"e_1_3_5_170_2","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.972029"},{"key":"e_1_3_5_171_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddt037"},{"key":"e_1_3_5_172_2","doi-asserted-by":"publisher","DOI":"10.1038\/71709"},{"key":"e_1_3_5_173_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213680"},{"key":"e_1_3_5_174_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2020.02.011"},{"key":"e_1_3_5_175_2","doi-asserted-by":"publisher","DOI":"10.1097\/PHM.0b013e31804b1d66"},{"key":"e_1_3_5_176_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep20193"},{"key":"e_1_3_5_177_2","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.050352"},{"key":"e_1_3_5_178_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn320"},{"key":"e_1_3_5_179_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddg157"},{"key":"e_1_3_5_180_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200303168"},{"key":"e_1_3_5_181_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24332"},{"key":"e_1_3_5_182_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2014.07.024"},{"key":"e_1_3_5_183_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10485"},{"key":"e_1_3_5_184_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01497-7"},{"key":"e_1_3_5_185_2","doi-asserted-by":"publisher","DOI":"10.1177\/0883073815627882"},{"key":"e_1_3_5_186_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198"},{"key":"e_1_3_5_187_2","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.447"},{"key":"e_1_3_5_188_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04193-6"},{"key":"e_1_3_5_189_2","unstructured":"Kletzl H Heinig H Jaber B et al. Bioequivalence and food effect assessment for a new room-temperature risdiplam tablet formulation in healthy volunteers. https:\/\/medically.roche.com\/global\/en\/neuroscience\/cure-sma-2024\/medical-material\/CURESMA-2024-poster-kletzl-bioequivalence-and-food-effect-assessment-pdf.html (2024 accessed April 14 2026)."},{"key":"e_1_3_5_190_2","unstructured":"Novartis. Novartis receives FDA approval for Itvisma\u00ae the only gene replacement therapy for children two years and older teens and adults with spinal muscular atrophy (SMA). https:\/\/www.novartis.com\/news\/media-releases\/novartis-receives-fda-approval-itvisma-only-gene-replacement-therapy-children-two-years-and-older-teens-and-adults-spinal-muscular-atrophy-sma (2025 accessed April 13 2026)."},{"key":"e_1_3_5_191_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002445"},{"key":"e_1_3_5_192_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702752"},{"key":"e_1_3_5_193_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.26.4.1333-1346.2006"},{"key":"e_1_3_5_194_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001777"},{"key":"e_1_3_5_195_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13040492"},{"key":"e_1_3_5_196_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddr600"},{"key":"e_1_3_5_197_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2012.211"},{"key":"e_1_3_5_198_2","unstructured":"Biogen. Spinraza prescribing information 2020. https:\/\/www.spinraza.com\/content\/dam\/commercial\/spinraza\/caregiver\/en_us\/pdf\/spinraza-prescribing-information.pdf (accessed October 20 2022 2022)."},{"key":"e_1_3_5_199_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31408-8"},{"key":"e_1_3_5_200_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(21)00100-0"},{"key":"e_1_3_5_201_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710504"},{"key":"e_1_3_5_202_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27187"},{"key":"e_1_3_5_203_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.09.007"},{"key":"e_1_3_5_204_2","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.70528"},{"key":"e_1_3_5_205_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-221600"},{"key":"e_1_3_5_206_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06698-9"},{"key":"e_1_3_5_207_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02065-z"},{"key":"e_1_3_5_208_2","volume-title":"Spinraza. Spinraza","year":"2024","unstructured":"Spinraza. Spinraza. https:\/\/www.spinraza.com\/ (2024, accessed October 24 2024)."},{"key":"e_1_3_5_209_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-221667"},{"key":"e_1_3_5_210_2","unstructured":"Biogen. FDA Approves New High Dose Regimen of SPINRAZA\u00ae (nusinersen) for Spinal Muscular Atrophy. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/fda-approves-new-high-dose-regimen-spinrazar-nusinersen-spinal (2026 accessed May 3 2026)."},{"key":"e_1_3_5_211_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2022.12.010"},{"key":"e_1_3_5_212_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1515"},{"key":"e_1_3_5_213_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302134"},{"key":"e_1_3_5_214_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.5.3227-3234.1996"},{"key":"e_1_3_5_215_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01483-7"},{"key":"e_1_3_5_216_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddad202"},{"key":"e_1_3_5_217_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-022-00338-1"},{"key":"e_1_3_5_218_2","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00037-x"},{"key":"e_1_3_5_219_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24203"},{"key":"e_1_3_5_220_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.1272"},{"key":"e_1_3_5_221_2","unstructured":"Novartis. Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset. https:\/\/www.novartis.com\/news\/media-releases\/novartis-shares-zolgensma-long-term-data-demonstrating-sustained-durability-75-years-post-dosing-100-achievement-all-assessed-milestones-children-treated-prior-sma-symptom-onset (2023 accessed March 25 2023 2023)."},{"key":"e_1_3_5_222_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2026.103867"},{"key":"e_1_3_5_223_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00001-6"},{"key":"e_1_3_5_224_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00251-9"},{"key":"e_1_3_5_225_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01866-4"},{"key":"e_1_3_5_226_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01867-3"},{"key":"e_1_3_5_227_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.001"},{"key":"e_1_3_5_228_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.015"},{"key":"e_1_3_5_229_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200676"},{"key":"e_1_3_5_230_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101296"},{"key":"e_1_3_5_231_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01974-7"},{"key":"e_1_3_5_232_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3389"},{"key":"e_1_3_5_233_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2012.112"},{"key":"e_1_3_5_234_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301541"},{"key":"e_1_3_5_235_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.10.018"},{"key":"e_1_3_5_236_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2006.03.008"},{"key":"e_1_3_5_237_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.03.020"},{"key":"e_1_3_5_238_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.52"},{"key":"e_1_3_5_239_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.06.004"},{"key":"e_1_3_5_240_2","doi-asserted-by":"publisher","DOI":"10.1177\/10430342251366314"},{"key":"e_1_3_5_241_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.12.067"},{"key":"e_1_3_5_242_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2022.05.001"},{"key":"e_1_3_5_243_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210268"},{"key":"e_1_3_5_244_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.210"},{"key":"e_1_3_5_245_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061764"},{"key":"e_1_3_5_246_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-221560"},{"key":"e_1_3_5_247_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2021.255"},{"key":"e_1_3_5_248_2","unstructured":"Novartis. Novartis announces AVXS-101 intrathecal study update. https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-avxs-101-intrathecal-study-update (2019 accessed October 11 2022 2022)."},{"key":"e_1_3_5_249_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04103-w"},{"key":"e_1_3_5_250_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04233-9"},{"key":"e_1_3_5_251_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04119-2"},{"key":"e_1_3_5_252_2","unstructured":"Wire B. FDA Approves Genentech\u2019s Evrysdi (risdiplam) for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA). https:\/\/www.businesswire.com\/news\/home\/20220530005033\/en\/FDA-Approves-Genentech (2022 accessed October 11 2022 2022)."},{"key":"e_1_3_5_253_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00741"},{"key":"e_1_3_5_254_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0384-5"},{"key":"e_1_3_5_255_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13786"},{"key":"e_1_3_5_256_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2009965"},{"key":"e_1_3_5_257_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00339-8"},{"key":"e_1_3_5_258_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.10.002"},{"key":"e_1_3_5_259_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02455-x"},{"key":"e_1_3_5_260_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00367-7"},{"key":"e_1_3_5_261_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11560-1"},{"key":"e_1_3_5_262_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27804"},{"key":"e_1_3_5_263_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410120"},{"key":"e_1_3_5_264_2","unstructured":"Genentech. Evrysdi prescribing information. https:\/\/www.gene.com\/download\/pdf\/evrysdi_prescribing.pdf (2022 accessed April 3 2023 2023)."},{"key":"e_1_3_5_265_2","unstructured":"Roche. FDA approves Roche\u2019s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA). https:\/\/www.roche.com\/media\/releases\/med-cor-2025-02-12 (2025 accessed April 14 2026)."},{"key":"e_1_3_5_266_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-0755"},{"key":"e_1_3_5_267_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)56388-2"},{"key":"e_1_3_5_268_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2023.108360"},{"key":"e_1_3_5_269_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI193956"},{"key":"e_1_3_5_270_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12318-z"},{"key":"e_1_3_5_271_2","unstructured":"CureSMA. State of SMA: 2024 Report. https:\/\/www.curesma.org\/wp-content\/uploads\/2025\/04\/State-of-SMA-Report2024_vWeb-4.pdf (2024) accessed April 22 2026."},{"key":"e_1_3_5_272_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2026.104520"},{"key":"e_1_3_5_273_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101379"},{"key":"e_1_3_5_274_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094809"},{"key":"e_1_3_5_275_2","unstructured":"Biogen. Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-presents-additional-salanersen-data-showing-new-motor (2026 accessed April 13 2026)."},{"key":"e_1_3_5_276_2","doi-asserted-by":"publisher","DOI":"10.1038\/387083a0"},{"key":"e_1_3_5_277_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1069525"},{"key":"e_1_3_5_278_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00107.2003"},{"key":"e_1_3_5_279_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040933"},{"key":"e_1_3_5_280_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.0030079"},{"key":"e_1_3_5_281_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.23.12457"},{"key":"e_1_3_5_282_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.012293"},{"key":"e_1_3_5_283_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209151"},{"key":"e_1_3_5_284_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1419791"},{"key":"e_1_3_5_285_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00225-X"},{"key":"e_1_3_5_286_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81669-8"},{"key":"e_1_3_5_287_2","unstructured":"CureSMA. Genentech Issues Community Letter Regarding Emugrobart. https:\/\/www.curesma.org\/genentech-issues-community-letter-regarding-emugrobart\/ (2026 accessed April 13 2026)."},{"key":"e_1_3_5_288_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00570-w"},{"key":"e_1_3_5_289_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910273"},{"key":"e_1_3_5_290_2","volume-title":"Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity","author":"Biohaven","year":"2024","unstructured":"Biohaven. Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity, 2024."},{"key":"e_1_3_5_291_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn156"},{"key":"e_1_3_5_292_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddm367"},{"key":"e_1_3_5_293_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado7189"},{"key":"e_1_3_5_294_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.70208"},{"key":"e_1_3_5_295_2","volume-title":"Report on the 7th Ottawa International Conference on Neuromuscular Disease & Biology \u2013 September 11-13","author":"Warman-Chardon J","year":"2025","unstructured":"Warman-Chardon J, Jasmin BJ, Kothary R, et al. Report on the 7th Ottawa International Conference on Neuromuscular Disease & Biology \u2013 September 11-13. , 2025. under review 2026."},{"key":"e_1_3_5_296_2","volume-title":"Clinical Trials","author":"Argenx","year":"2026","unstructured":"Argenx. Clinical Trials, 2026. https:\/\/clinicaltrials.argenx.com\/sparkle (accessed July 15 2026)."},{"key":"e_1_3_5_297_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk9109"},{"key":"e_1_3_5_298_2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-2-44"},{"key":"e_1_3_5_299_2","unstructured":"NMD-Pharma. NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy. https:\/\/www.nmdpharma.com\/news\/nmd-initiates-phase-2-trial-of-nmd670-in-sma (2023 accessed April 13 2025)."},{"key":"e_1_3_5_300_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2026.02.050"},{"key":"e_1_3_5_301_2","unstructured":"GEMMABio. GEMMABio Announces First Patient Dosed in CHARISMA Trial of GB221 Investigational Next-Generation Gene Therapy for Spinal Muscular Atrophy Type 1 SMA1. https:\/\/www.prnewswire.com\/news-releases\/gemmabio-announces-first-patient-dosed-in-charisma-trial-of-gb221-investigational-nextgeneration-gene-therapy-for-spinal-muscular-atrophy-type-1-sma1-302698146.html (226 accessed April 30 2026)."},{"key":"e_1_3_5_302_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00753-7"},{"key":"e_1_3_5_303_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2026.0641"},{"key":"e_1_3_5_304_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-020-00624-2"},{"key":"e_1_3_5_305_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01695-7"},{"key":"e_1_3_5_306_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00477-6"},{"key":"e_1_3_5_307_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199903)45:3<337::AID-ANA9>3.0.CO;2-U"},{"key":"e_1_3_5_308_2","first-page":"4061","article-title":"A severe mouse model of spinal muscular atrophy develops early systemic inflammation","volume":"27","author":"Wan B","year":"2018","unstructured":"Wan B, Feng P, Guan Z, et al. A severe mouse model of spinal muscular atrophy develops early systemic inflammation. Human molecular genetics 2018; 27: 4061\u20134076, Research Support, Non-U.S. Gov't 2018\/08\/24. https:\/\/doi.org\/10.1093\/hmg\/ddy300","journal-title":"Human molecular genetics"},{"key":"e_1_3_5_309_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03857-3"},{"key":"e_1_3_5_310_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70132"},{"key":"e_1_3_5_311_2","unstructured":"AJMC. The Future of Disease-Modifying Therapies for Patients With SMA. https:\/\/www.ajmc.com\/view\/the-future-of-disease-modifying-therapies-for-patients-with-sma (2025 accessed April 13 2026)."}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864261480901","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864261480901","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864261480901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:52:18Z","timestamp":1789386738000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864261480901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":310,"alternative-id":["10.1177\/17562864261480901"],"URL":"https:\/\/doi.org\/10.1177\/17562864261480901","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"17562864261480901"}}